Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 8/20 | 1.00 |
| ▸ | NFKBIA | P25963 | 8/20 | 1.00 |
| ▸ | SLC40A1 | Q9NP59 | 12/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11973889 | 0.71 | SLC40A1 (1.00) | RELANFKBIASLC40A1KDM4EALDH1A1 | |
| SCHEMBL11997112 | 0.68 | SLC40A1 (0.77) | RELANFKBIASLC40A1 | |
| SCHEMBL11972877 | 0.66 | SLC40A1 (1.00) | RELANFKBIASLC40A1KDM4EALDH1A1 | |
| SCHEMBL416275 | 0.65 | NFKBIA (1.00) | RELANFKBIASLC40A1 | |
| SCHEMBL11973219 | 0.64 | SLC40A1 (1.00) | RELANFKBIASLC40A1KDM4EALDH1A1 | |
| SCHEMBL1666180 | 0.62 | CHEK1 (0.62) | RELANFKBIASLC40A1KDM4EALDH1A1 | |
| SCHEMBL32689426 | 0.62 | CHEK1 (0.62) | RELANFKBIASLC40A1KDM4EALDH1A1 | |
| SCHEMBL15886690 | 0.61 | CCR1 (0.50) | RELANFKBIAKDM4EALDH1A1 | |
| SCHEMBL2907484 | 0.61 | CCR1 (0.45) | RELANFKBIAKDM4EALDH1A1HSD17B10 | |
| SCHEMBL12475341 | 0.61 | SLC40A1 (0.80) | RELANFKBIASLC40A1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120064099-A1 | COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120064099-A1 | COMPOUNDS THAT INHIBIT NFKB AND BACE1 ACTIVITY | NFKBIA, BACE1, BACE2 | RELA 10/4885NFKBIA 1/4885SLC40A1 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.